Aligos’ licensing deal in China broadens trial scope, secures immediate $25m
Aligos Therapeutics’ recent China licensing deal for chronic hepatitis B therapies enables it to broaden clinical development, generate more data, and tap into the world’s largest market for these treatments.Aligos Therapeutics’...To view the full article, register now.
Already a subscriber? Click here to view full article